Armodafinil for excessive daytime sleepiness

Drugs of Today

Volumn 44, Issue 6, 2008, Pages 395-414

  Nishino, Seiji ^a   Okuro, Masashi ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; ARMODAFINIL; CENTRAL STIMULANT AGENT; DEXAMPHETAMINE; DEXTRO METHAMPHETAMINE; FENCAMFAMIN; HYPNOTIC AGENT; KETANSERIN; MAZINDOL; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; MUSCIMOL; PEMOLINE; PLACEBO; PRAZOSIN; VANOXERINE; XANTHINE DERIVATIVE;

ABDOMINAL PAIN; CLINICAL TRIAL; DAYTIME SOMNOLENCE; DELUSION; DISEASE ASSOCIATION; DIZZINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSPNEA; ELECTROENCEPHALOGRAM; ELECTROMYOGRAM; FATIGUE; FOOD AND DRUG ADMINISTRATION; HALLUCINATION; HEADACHE; HEART PALPITATION; HUMAN; HYPERSOMNIA; INSOMNIA; LIVER TOXICITY; LOW DRUG DOSE; MANIA; MENTAL DISEASE; NARCOLEPSY; NAUSEA; NEURASTHENIA; NEUROBIOLOGY; NONHUMAN; POSITIVE END EXPIRATORY PRESSURE; PREVALENCE; RASH; REVIEW; RHINITIS; SHIFT WORKER; SIDE EFFECT; SLEEP APNEA SYNDROME; SLEEP DISORDER; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SUICIDAL IDEATION; T WAVE; TACHYCARDIA; THORAX PAIN; WAKEFULNESS;

ANIMALS; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; NARCOLEPSY; SLEEP APNEA, OBSTRUCTIVE; SLEEP DISORDERS; SLEEP DISORDERS, CIRCADIAN RHYTHM; WAKEFULNESS;

EID: 49149089673     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2008.44.6.1223892     Document Type: Review

References (84)

1. Nuvigil™ (armodafinil) tablets. Available at: http://www.cephalon.com/newsroom/assets/nuvigil_prescribing information.pdf.
2. Wong, Y.N., Simcoe, D., Hartman, L.N. et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 1999, 39(1): 30-40.
3. Wong, Y.N., King, S.P., Simcoe, D. et al. Open-label, single-dose pharmacokinetic study of modafinil tablets: Influence of age and gender in normal subjects. J Clin Pharmacol 1999, 39(3): 281-8.
4. Robertson, P. Jr., Hellriegel, E.T. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003, 42(2): 123-37.
5. In, Y., Tomoo, K., Ishida, T., Sakamoto, Y. Crystal and molecular structure of an (S)-(+)-enantiomer of modafinil, a novel wake-promoting agent. Chem Pharm Bull (Tokyo) 2004, 52(10): 1186-9.
6. Harsh, J.R., Hayduk, R., Rosenberg, R. et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 2006, 22(4): 761-74.
7. Roth, T., White, C., Schmidt-Nowara, W. et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: A 12-week, multicenter, double-blind, random ized, placebo-controlled study in nCPAP-adherent adults. Clin Ther 2006, 28(5): 689-706.
8. Hirshkowitz, M., Black, J.E., Wesner, K., Niebler, G., Arora, S., Roth, T. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Respir Med 2007, 101(3): 616-27.
9. Drake, C., Walsh, J., Roth, T. Armodafinil improves sleep latency in patients with shift work sleep disorder. Sleep 2006, 29: Abst 0189.
10. Wise, M., Arand, D.L., Auger, R.R., Brooks, S.N., Watson, N.F., American Academy of Sleep Medicine. Treatment of narcolepsy and other hypersomnia of central origin: American Academy of Sleep Medicine Review. Sleep 2007, 30(12): 1712-27.
11. Nishino, S., Mignot, E. CNS stimulants in sleep medicine: Basic mechanisms and pharmacology. In: Principles and Practice of Sleep Medicine, 4th ed. Kryger, M.H., Roth, T., Dement, W.C. Dement (Eds.). Elsvier Saunders: Philadelphia 2005, 468-98.
12. Nishino, S. Clinical and neurobiological aspects of narcolepsy. Sleep Med 2007, 8(4): 373-99.
13. ICSD-2-International Classification of Sleep Disorders, 2nd Ed.: Diagnostic and Coding Manual. A.A.o.S. Medicine. American Academy of Sleep Medicine: Westchester 2005.
14. Nishino, S., Ripley, B, Overeem, S., Lammers, G.J., Mignot, E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000, 355(9197): 39-40.
15. Peyron, C., Faraco, J., Rogers, W. et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000, 6(9): 991-7.
16. Mignot, E., Lammers, G.J., Ripley, B. et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002, 59(10): 1553-62.
17. Veasey, S.C., Guilleminault, C., Strohl, K.P., Sanders, M.H., Ballard, R.D., Magalang, U.J. Medical therapy for obstructive sleep apnea: A review by the Medical Therapy for Obstructive Sleep Apnea Task Force of the Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep 2006, 29(8): 1036-44.
18. Weaver, T.E., George, C. Cognition and performance in patients with obstructive sleep apnea-hypopnea. In: Principles and Practice of Sleep Medicine, 4th Ed. Kryger, M.H., Roth, T., Dement, W.C. (Eds.). Elsvier Saunders: Philadelphia 2005, 1023-33.
19. Monk, T.H. Shift work: Basic principles. In: Principles and Practice of Sleep Medicine, 4th Ed. Kryger, M.H., Roth, T., Dement, W.C. (Eds.). Elsvier Saunders: Philadelphia 2005, 673-9.
20. Czeisler, C.A., Walsh, J.K., Roth, T. et al. Modafinil for excessive sleepiness associated with shift-work sleep disorder. N Engl J Med 2005, 353(5): 476-86.
21. Bastuji, H., Jouvet, M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiatry 1988, 12(5): 695-700.
22. Broughton, R.J., Fleming, J.A., George, C.F. et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997, 49(2): 444-51.
23. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology 2000, 54(5): 1166-75.
24. Hermant, J., Rambert, F.A., Duteil, J. Awakening properties of modafinil: Effect on nocturnal activity in monkeys (Macaca mulatta) after acute and repeated administration. Psychopharmacology 1991, 103(1): 28-32.
25. Modafinil (Provigil) product information. Available at: http://www.google.com/search?q=mitral+modafinil+AND+mitral+valve+prolapse+& hl=en&client=firefox-a&rls=org. mozilla:en-US:official&hs= Vhj&start= 10&sa=N.
26. Malcolm, R., Book, S.W., Moak, D., DeVane, L., Czepowicz, V. Clinical applications of modafinil in stimulant abusers: Low abuse potential. Am J Addict 2002, 11(3): 247-9.
27. Jasinski, D.R. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 2000, 14(1): 53-60.
28. Gold, L.H., Balster, R.H. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology 1996, 126(4): 286-92.
29. Brun, J., Chamba, G. Khalfallah, Y. et al. Effect of modafinil on plasma melatonin, cortisol and growth hormone rhythms, rectal temperature and performance in healthy subjects during a 36 h sleep deprivation. J Sleep Res 1998, 7(2): 105-14.
30. Turner, D.C., Robbins, T.W., Clark, L., Aron, A.R., Dowson, J., Sahakian, B.J. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl) 2003, 165(3): 260-9.
31. The Off-Label Use of Modafinil. [Available at: http://pharmacy.oregonstate.edu/drug_policy/pages/dur_board/reviews/articles/ modafinil.html.
32. Minzenberg, M.J., Carter, C.S. Modafinil: A review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008, 33(7): 1477-502.
33. Ballon, J.S., Feifel, D. A systematic review of modafinil: Potential clinical uses and mechanisms of action. J Clin Psychiatry 2006, 67(4): 554-66.
34. MacDonald, J.R., Hill, J.D., Tarnopolsky, M.A. Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy. Neurology 2002, 59(12): 1876-80.
35. Camfferman, D., McEvoy, R.D., O'Donoghue, F., Lushington, K. Prader Willi Syndrome and excessive daytime sleepiness. Sleep Med Rev 2008, 12(1): 65-75.
36. Högl, B., Saletu, M., Brandauer, E. et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: A double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002, 25(8): 905-9.
37. Nieves, A.V., Lang, A.E. Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. Clin Neuropharmacol 2002, 25(2): 111-4.
38. Randall, D.C., Viswanath, A., Bharania, P. et al. Does modafinil enhance cognitive performance in young volunteers who are not sleep-deprived? J Clin Psychopharmacol 2005, 25(2): 175-9.
39. Baranski, J.V., Pigeau, R., Dinich, P., Jacobs, I. Effects of modafinil on cognitive and meta-cognitive performance. Hum Psychopharmacol 2004, 19(5): 323-32.
40. Ferris, R.M., Tang, F.L., Maxwell, R.A. A comparison of the capacities of isomers of amphetamine, deoxypipradrol and methylphenidate to inhibit the uptake of tritiated catecholamines into rat cerebral cortex slices, synaptosomal preparations of rat cerebral cortex, hypothalamus and striatum and into adrenergic nerves of rabbit aorta. J Pharmacol Exp Ther 1972, 181(3): 407-16.
41. Donovan, J.L., Malcolm, R.J., Markowitz, J.S., DeVane, C.L. Chiral analysis of d- and I-modafinil in human serum: Application to human pharmacokinetic studies. Ther Drug Monit 2003, 25(2): 197-202.
42. Dinges, D.F., Arora, S., Darwish, M., Niebler, G.E. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr Med Res Opin 2006, 22(1): 159-67.
43. Robertson, P. Jr., Hellriegel, E.T., Arora, S., Nelson, M. Effect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers. J Clin Pharmacol 2002, 42(2): 205-14.
44. Wisor, J.P., Dement, W.C, Aimone, L., Williams, M., Bozyczko-Coyne, D. Armodafinil, the R-enantiomer of modafinil: Wake-promoting effects and pharmacokinetic profile in the rat. Pharmacol Biochem Behav 2006, 85(3): 492-9.
45. Edgar, D.M., Seidel, W.F. Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. J Pharmacol Exp Ther 1997, 283(2): 757-69.
46. Black, J.E., Hirshkowitz, M. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. Sleep 2005, 28(4): 464-71.
47. Schwartz, J.R., Hirshkowitz, M., Erman, M.K., Schmidt-Nowara, W. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea: A 12-week, open-label study. Chest 2003, 124(6): 2192-9.
48. Jones, B. E. Basic mechanism of sleep-wake states. In: Principles and Practice of Sleep Medicine, 4th Ed. Kryger, M.H., Roth, T., Dement, W.C. (Eds.). Elsvier Saunders: Philadelphia 2005, 136-53.
49. Jouvet, M. The role of monoamines and acethylcholine-containing neurons in the regulation of the sleep-waking cycle. Ergebn Physiol 1972, 64: 166-307.
50. Nishino, S., Mignot, E., Dement, W.C. Sedative-hypnotics. In: Textbook of Psychopharmacology. Schatzberg, A.F., Nemeroff, C.B. (Eds.). American Psychiatric Press: Washington, D.C., 2004, 651-84.
51. Steinfels, G.F., Heym, J., Strecker, R.E., Jacobs, B.L. Behavioral correlates of dopaminergic activity in freely moving cats. Brain Res 1983, 258(2): 217-28.
52. Björklund, A., Lindvall, O. Dopamine-containing systems in the CNS. In: Handbook of Chemical Neuroanatomy, Vol. 2, Classical Transmitter in the CNS, Part I. Bjorklund, A., Hokfelt, T. (Eds.). Elsevier: Amsterdam 1984, 55-121.
53. Trulson, M.E. Simultaneous recording of substantia nigra neurons and voltametric release of dopamine in the caudate of behaving cats. Brain Res Bull 1985, 15(2): 221-3.
54. Ljungberg, T., Apicella, P., Schultz, W. Responses of monkey dopamine neurons during learning of behavioral reactions. J Neurophysiol 1992, 67(1): 145-63.
55. Jones, B.E., Bobillier, P., Pin, C., Jouvet, M. The effect of lesions of catecholamine-containing neurons upon monoamine content of the brain and EEG and behavioral waking in the cat. Brain Res 1973, 58(1): 157-77.
56. Lu, J., Jhou, T.C., Saper, C.B. Identification of wake-active dopaminergic neurons in the ventral periaqueductal gray matter. J Neurosci 2006, 26(1): 193-202.
57. Moller, J.C., Stiasny, K., Cassel, W., Peter, J.H., Krüger, H.P., Oertel, W.H. ["Sleep attacks" in Parkinson patients. A side effect of nonergoline dopamine agonists or a class effect of dopamine agonists?]. Nervenarzt 2000, 71(8): 670-6.
58. Kuczenski, R., Segal, D.S. Neurochemistry of amphetamine. In: Psychopharmacology, Toxicology and Abuse. Cho, A.K., Segel, D.S. (Eds.). Academic Press: San Diego 1994, 81-113.
59. Nishino, S., Mao, J., Sampathkumaran, R., Shelton, J. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Research Online 1998, 1: 49-61. http://www.sro.org/1998/ Nishino/49/.
60. Kanbayashi, T. et al. Differential effects of D-and L-amphetamine isomers on dopaminergic transmission: Implication for the control of alertness in canine narcolepsy. Sleep Res 1997, 26: 383.
61. Mignot, E., Nishino, S., Guilleminault, C., Dement, W.C. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994, 17(5): 436-7.
62. Tanganelli, S., Fuxe, K., Ferraro, L., Janson, A.M., Bianchi, C. Inhibitory effects of the psychoactive drug modafinil on gamma-aminobutyric acid outflow from the cerebral cortex of the awake freely moving guinea pig. Naunyn Schmiedebergs Arch Pharmacol 1992, 345(4): 461-5.
63. Lin, J.S., Roussel, B., Akaoka, H., Fort, P., Debilly, G., Jouvet, M. Role of catecholamines in modafinil and amphetamine induced wake-fulness, a comparative pharmacological study. Brain Res 1992, 591(2): 319-26.
64. Ferraro, L., Tanganelli, S., O'Connor, W.T., Antonelli, T., Rambert, F., Fuxe, K. The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. Eur J Pharmacol 1996, 306(1-3): 33-9.
65. Duteil, J., Rambert, F.A., Pessonnier, J., Hermant, J.F., Gombert, R., Assous, E. Central α1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil: Studies with experimental animals. Eur J Pharmacol 1990, 180(1): 49-58.
66. Dopheide, M.M., Morgan, R.E., Rodveit, K.R., Schachtman, T.R., Miller, D.K. Modafinil evokes striatal [3H]dopamine release and alters the subjective properties of stimulants. Eur J Pharmacol 2007, 568(1-3): 112-23.
67. Wisor, J.P., Nishino, S., Sora, I., Uhl, G.H., Mignot, E., Edgar, D.M. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001, 21(5): 1787-94.
68. Shelton, J., Nishino, S., Vaught, J., Dement, W.C., Mignot, E. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep 1995, 18(10): 817-26.
69. Nishino, S., Fruhstorfer, B., Arrigoni, J., Guilleminault, C., Dement, W.C., Mignot, E. Further characterization of the alpha-1 receptor subtype involved in the control of cataplexy in canine narcolepsy. J Pharmacol Exp Ther 1993, 264(3): 1079-84.
70. Korotkova, T.M., Klyuch, B.P., Ponomarenko, A.A., Lin, J.S., Haas, H.L., Sergeeva, O.A. Modafinil inhibits rat midbrain dopaminergic neurons through D2-like receptors. Neuropharmacology 2007, 52(2): 626-33.
71. Nissbrandt, N., Engberg, G., Pileblad, E. The effects of GBR 12909, a dopamine re-uptake inhibitor, on monoaminergic neurotransmission in rat striatum, limbic forebrain, cortical hemispheres and substantia nigra. Naunyn Schmiedebergs Arch Pharmacol 1991, 344(1): 16-28.
72. Ciliax, B.J., Heilman, C., Demchyshyn, L.L. et al. The dopamine transporter: Immunochemical characterization and localization in brain. J Neurosci 1995, 15(3): 1714-23.
73. Lin, J.S., Hou, Y., Jouvet, M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cats. Proc Natl Acad Sci USA 1996, 93(24): 14128-33.
74. Chemelli, R.M., Willie, J.T., Sinton, C.M. et al. Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation. Cell 1999, 98(4): 437-51.
75. Scammell, T.E., Estabrooke, I.V., McCarthy, M.T. et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000, 20(22): 8620-8.
76. Ishizuka, T., Sakamoto, Y., Sakurai, T., Yamatodani, A. Modafinil increases histamine release in the anterior hypothalamus of rats. Neurosci Lett 2003, 339(2): 143-6.
77. Gallopin, T., Luppi, P.H., Rambert, F.A., Frydman, A., Fort, P. Effect of the wake-promoting agent modafinil on sleep-promoting neurons from the ventrolateral preoptic nuclueus: An in vitro pharmacologic study. Sleep 2004, 27(1): 19-25.
78. Madras, B.K., Xie, Z., Lin, Z. et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 2006, 319(2): 561-9.
79. Bonaventure, P., Letavic, M., Dugovic, C. et al. Histamine H3 receptor antagonists: From target identification to drug leads. Biochem Pharmacol 2007, 73(8): 1084-96.
80. Riehl, J., Honda, K., Kwan, M., Hong, J., Mignot, E., Nishino, S. Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy. Neuropsychopharmacology 2000, 23(1): 34-45.
81. Nishino, S., Arhgoni, J., Shelton, J., Kanbayashi, T., Dement, W.C., Mignot, E. Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J Neurosci 1997, 17(16): 6401-8.
82. Porkka-Heiskanen, T., Kalinchuk, A., Alanko, L., Urrila, A., Stenberg, D. Adenosine, energy metabolism, and sleep. ScientificWorldJournal 2003, 3(8): 790-8.
83. Mignot, E., Taheri, S., Nishino, S. Sleeping with the hypothalamus: Emerging therapeutic targets for sleep disorders. Nat Neurosci 2002, 5(Suppl.): 1-6.
84. Fujiki, N., Nishino, S. Hypocretin/orexin replacement therapy in hypocretin/orexin deficient narcolepsy: An overview. In: The Orexin/Hypocretin System: Physiology and Pathophysiology. Nishino, S., Sakurai, T. (Eds.). Humana Press: Totowa 2006, 367-88.